Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel transplant regimen improves survival in primary immunodeficiency

Key clinical point: Allogeneic hematopoietic stem cell transplantation following a novel conditioning regimen showed success in adults and children with primary immunodeficiency.

Major finding: The 1-year overall survival and graft failure–free/graft-versus-host disease–free survival was 98% and 82%, respectively.

Study details: A prospective clinical trial involving 29 children and adults with various types of primary immunodeficiency.

Disclosures: Dr. Dimitrova reported having no financial disclosures.

Citation:

Dimitrova D et al. TCT 2019, Abstract 54.